

# **POTENTIATION OF ANTI-CD38-IMMUNOTOXIN CYTOTOXICITY**

## **BACKGROUND OF THE INVENTION**

### **Field of the Invention**

The present invention relates generally to the fields of immunology and tumor biology. More specifically, the present invention relates to treatment for the enhancement of CD38 protein expression in target tumor cells to increase the cytotoxicity of anti-CD38 based immunotoxins.

## Description of the Related Art

The use of monoclonal antibodies for delivering drugs or toxins to distinct molecular structures expressed on the surface of unwanted tumor cells represents an attractive and potentially useful strategy. Theoretically, such a targeted approach to cancer therapy could offer a major advance in the selective elimination of tumor cells while reducing the toxicity of treatment towards normal non-target tissues. Nevertheless, in practice many problems exist that need to be addressed before immunotoxin or antibody-drug therapies can be truly effective *in vivo*.

One potential limitation to the success of any targeted approach to therapy is the heterogeneity of target antigen expression within a population of tumor cells. It follows that if a small number of cells within a tumor were negative for the target antigen or expressed the antigen only very weakly, then these cells could possibly escape destruction due to a failure of antibody-mediated delivery of the cytotoxic agent to those particular cells. A possible means of overcoming this problem would be to identify agents that induce high levels of cell surface target molecules, in the expectation that target tumor cells which were antigen negative would express these target molecules in abundance.

All-*trans*-retinoic acid (RA) is an agent that induces high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. Retinoic acid-induced expression of CD38 in these cells is specific, rapid, dose-dependent, and highly sensitive, with 4-fold induction at as low a dose of retinoic acid as  $10^{-13}$  M. The induction of CD38 expression by retinoic acids has been shown to involve the RAR $\alpha$  retinoid receptor. RAR receptors form heterodimers with RXR receptors; the RXR/RAR heterodimer then interacts with DNA sequences known as retinoic acid response elements (RARE's) which are involved in retinoid-induced transcription.

CD38 is a 45-kDa cell surface protein which is primarily expressed by early progenitor and mature activated cells of the hematopoietic system. It is a transmembrane glycoprotein with a short N-terminal cytoplasmic domain and a long C-terminal extracellular domain. The extracellular domain has been shown to be a bifunctional enzyme having ADP-ribosyl cyclase as well as ADP-ribosyl hydrolase activities in that it catalyzes the conversion of NAD<sup>+</sup> to cADPR (cyclase) and can further hydrolyze it to ADP-ribose (hydrolase). cADPR is involved in the mobilization of calcium from intracellular stores which is a second messenger activity important

for cellular proliferation, differentiation, and apoptosis. CD38 is believed to act as a receptor for an unidentified ligand and to act as a cell adhesion molecule by interacting with CD31. Experiments in which CD38 function was activated by monoclonal antibodies directed against it have implicated CD38 in proliferation of mature B lymphocytes and myeloid leukemia cells, rescue of germinal center cells from apoptosis, and growth suppression of stroma-supported cultures of B-cell progenitors as well as induction of the cytokines IL-6, IL-1, GM-CSF, and IL-10. In addition, it has been shown to signal an increase in TNF- $\alpha$ , IL-1, IL-6, and IL-8 transcription in myeloid leukemia cells.

The prior art is deficient in the lack of a method to induce the expression of a target molecule for immunotherapy of tumor and other disease-causing cells. The present invention fulfills this longstanding need and desire in the art.

## SUMMARY OF THE INVENTION

The present invention demonstrates the potential of retinoid-induced CD38 expression to serve as a target for delivering

the immunotoxin anti-CD38-gelonin. The results obtained suggested that retinoic acid treatment of leukemia cells, even at very low concentrations (subnanomolar) makes these cells exquisitely sensitive to immunotoxin-induced killing.

5           The current invention comprises a method of treating an individual having a pathophysiological state, comprising the step of administering to said individual a pharmacologically effective dose of an agent which upregulates the expression of a cellular target and also administering a pharmacologically effective dose of an  
10 immunotoxin directed against the upregulated cellular target.

          The current invention also comprises a method of treating an individual having a pathophysiological state responsive to retinoid treatment, comprising the step of administering to said individual a pharmacologically effective dose of a retinoic acid  
15 metabolite and a pharmacologically effective dose of an immunotoxin.

          Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These  
20 embodiments are given for the purpose of disclosure.

## BRIEF DESCRIPTION OF THE DRAWINGS

So that the matter in which the above-recited features,  
5 advantages and objects of the invention, as well as others which will  
become clear, are attained and can be understood in detail, more  
particular descriptions of the invention briefly summarized above  
may be had by reference to certain embodiments thereof which are  
illustrated in the appended drawings. These drawings form a part  
10 of the specification. It is to be noted, however, that the appended  
drawings illustrate preferred embodiments of the invention and  
therefore are not to be considered limiting in their scope.

**Figure 1** shows a dot blot of mRNA from a variety of  
human tissues after hybridization with a radiolabeled human CD38-  
15 specific nucleic acid probe. Relatively low CD38 mRNA expression  
was observed only in thymus tissue [from both adult (E5) and fetal  
(G6)] while a lesser level of expression was seen in normal prostate  
(C7).

**Figure 2** shows the effects of 5 nM all-*trans*-retinoic  
20 acid (RA) on the cytotoxicity of the immunotoxin and the effects of  
adding increasing concentrations of the unconjugated anti-CD38

monoclonal antibody (IB4). Point C indicates the effect of immunotoxin alone. +IT (+RA) shows the effect of 5 nM all-*trans*-retinoic acid (RA) on the cytotoxicity of the immunotoxin. In the rest of the samples, increasing concentrations of IB4 were added along with immunotoxin and 5 nM all-*trans*-retinoic acid (RA). After 3 days of incubation, cell viability was determined with the MTS assay. The results are represented in terms of % surviving cells.

**Figure 3** shows effect of retinoic acid pretreatment on the cytotoxicity of anti-CD38 immunotoxin on HL-60 cells. HL-60 cells were incubated overnight in the presence or absence of retinoic acid. After removal of the media and twice washing the cells, the cells were reincubated with increasing concentrations of immunotoxin (represented as ng/well) in the presence or absence of 100-fold excess of unconjugated anti-CD38 monoclonal antibody IB4. After three days, the MTS assay was used to determine cell viability which is represented in terms of % surviving cells.

**Figure 4** shows the effect of treatment with either immunotoxin or gelonin on the viability of HL-60 cells. HL-60 cells were incubated for three days in increasing concentrations of either immunotoxin or gelonin (represented as ng/well toxin) in the presence or absence of 5 nM retinoic acid. Cell viability was

determined by the MTS assay and is represented here in terms of percent cell survival relative to the control sample (no toxin).

**Figure 5** shows the effect of increasing concentrations of all-*trans*-retinoic acid (RA) (in nM) on cell survival. HL-60 cells were incubated with either immunotoxin or unconjugated anti-CD38 monoclonal antibody in either the absence or the presence of increasing concentration of retinoic acid (shown in nM). After three days, cell viability was determined by MTS assay and is shown in terms of percentage of cell survival relative to an untreated control.

**Figure 6** shows the effect of increasing concentrations of immunotoxin (shown in ng/well) in either the presence or absence of 5 nM all-*trans*-retinoic acid (RA) on cell survival of different cell lines including Daudi, THP-1, K562 (which is resistant to RA-induced expression of CD38), and a RAR $\alpha$ -expressing variant of HL60. Cell viability was measured by the MTS assay after three days and is represented in terms of percent cell survival relative to an untreated control.

**Figure 7** shows the immunotoxin induced killing of Doxo-resistant HL-60 cells which are resistant to adriamycin-induced killing. The cells were incubated with increasing concentrations of immunotoxin (shown in ng/well) in either the presence or absence of

5 nM RA. Cell survival was assayed after 3 days using the MTS assay.

**Figure 8** shows the immunotoxin mediated killing of the non-Hodgkin lymphoma cell line MZ(NHL) that has a high basal expression of CD38 antigen. The cell were incubated with increasing concentrations of immunotoxin (shown in ng/well) in the presence or absence of 5 nM retinoic acid. After three days, cell viability was assayed with the MTS assay and is shown in terms of % viable cells.

**Figure 9** shows the immunotoxin mediated killing of the retinoic acid-resistant variant of the HL60 cell line (HL60R). These cells are resistant to retinoic acid-induced expression of the CD38 antigen due to a point mutation in the retinoic acid receptor alpha (RAR $\alpha$ ) gene. The cell line was cultured with increasing concentrations of immunotoxin (in ng/ml) under different conditions. After 3 days, cell viability was assayed by the MTS assay and is represented in terms of O.D. The presence of retinoic acid failed to promote immunotoxin-induced killing of these cells due to their inability to express CD38 antigen in response to retinoic acid treatment.

## DETAILED DESCRIPTION OF THE INVENTION

An immunotoxin is defined as any immunological molecule such as an antibody which has been conjugated with a toxin, preferably a cytotoxin.

The present invention is directed to a method of treating an individual having a pathophysiological state, comprising the step of administering to said individual an a pharmacologically effective dose of an agent which upregulates the expression of a cellular target. This administration is followed by the administration of a pharmacologically effective dose of an immunotoxin directed against the cellular target. Preferably, the administered agent is selected from the group consisting of differentiating agents, cytokines, interleukin-2, tumor necrosis factor, interferon- $\alpha$ , interferon- $\gamma$  and peptide hormones.

In one embodiment, the invention comprises the administration of a pharmacologically effective dose of a retinoid. Preferably, the retinoid induces expression of CD38 antigen in cells. If this is the case, a pharmacologically effective dose of a anti-CD38 immunotoxin is administered. Representative pathophysiological states which may be treated using the methods of this embodiment

of the invention include RAR $\alpha$  selective acute myeloid leukemia, acute promyelocytic leukemia, lymphomas, and myelomas.

Representative retinoic acid metabolites which may be used in the methods of the present invention include all-*trans*-retinoic acid (RA); 9-*cis* retinoic acid (9-*cis* RA); (*E*)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB); (*E*)-4-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-propenyl]benzoic acid (3-met TTNPB); and other retinoids that can bind and activate the RAR $\alpha$  receptor. Preferably, the retinoid is administered in a dose of from about 0.1 mg/kg to about 2 mg/kg.

The immunotoxin used in the methods of the present invention specifically target cells expressing the CD38 antigen. Preferably, the immunotoxin comprises a monoclonal antibody directed against the CD38 antigen conjugated to a toxin molecule. Although a person having ordinary skill in this art could substitute any toxin, a preferred toxin useful in these methods is gelonin. Although a person having ordinary skill in this art could substitute any monoclonal antibody specific for the CD38 antigen, IB4 or IB6 antibodies were used herein to demonstrate the present methods. Preferably, the immunotoxin is administered in a dose of from about

0.05 mg/kg to about 2 mg/kg.

The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.

### **EXAMPLE 1**

CD38 expression in normal tissues is limited mainly to the thymus.

The tissue specificity of CD38 was examined by the hybridization of a radiolabeled CD38 nucleic acid probe against a commercial (CLONTECH) tissue specific mRNA dot blot. The results of the hybridization are shown in Figure 1. It was observed that CD38 is mainly expressed in the thymus with significantly lower levels of expression in the prostate.

## EXAMPLE 2

Retinoic acid (RA) augments the cytotoxic effect of immunotoxin through enhanced expression of CD38.

5 HL-60 cells were incubated with either immunotoxin alone or in the presence of 5 nM retinoic acid (RA). Increasing concentrations of unconjugated IB4 monoclonal antibody were added to the cells incubated with immunotoxin and retinoic acid. After three days, the cells were assayed for viability with the MTS assay. 10 Briefly, 6.5 mg/ml MTS solution [(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and 0.5 mM PMS (phenazine methosulfate) solution were mixed at a ratio of 20:1. 20 µl of the combined MTS/PMS solution was placed in each well of a 96 well plate containing samples of the cells to be tested. 15 The plate was incubated for 1-4 hours at 37°C in a 5% CO<sub>2</sub> atmosphere, after which time, the amount of formazan produced by live cells from cellular reduction of MTS was measured by reading the absorbance at 490 nm. The results are shown in Figure 2.

20 Immunotoxin alone had little effect on the viability of the cells (C). However, when the cells were incubated with immunotoxin in the presence of 5 nM retinoic acid, a significant reduction in cell

viability was observed. Increasing concentrations of unconjugated IB4 monoclonal antibody blocked the cytotoxic effect of immunotoxin and retinoic acid. The fact that unconjugated IB4 blocked the ability of the immunotoxin to kill the cells demonstrates that the immunotoxin is specifically interacting with the CD38 surface marker and that the effect of the retinoic acid is to increase the expression of the CD38 antigen.

### EXAMPLE 3

#### All-*trans*-retinoic acid (RA) pretreatment enhances the induced killing of HL-60 Cells.

HL-60 cells were preincubated overnight in either the presence or absence of 5 nM all-*trans*-retinoic acid. The cells were washed twice and incubated in increasing concentrations of immunotoxin in either the presence or absence of IB4 unconjugated anti-CD38 MoAb. After three days, the cell were assayed for viability. The results are shown in Figure 3.

Preincubation with all-*trans*-retinoic acid followed by immunotoxin treatment resulted in more cell death than treatment

with immunotoxin alone. The presence of 100 fold excess of the unconjugated anti-CD38 monoclonal antibody IB4 blocked the toxicity of the immunotoxin in both cases by competing with the immunotoxin for access to the CD38 markers on the cells. These results demonstrate that the all-*trans*-retinoic acid (RA) was causing some change in the cells which render them more susceptible to the immunotoxin rather than playing a direct role in the death of the target cells.

#### **EXAMPLE 4**

Gelonin must be conjugated to the anti-CD38 antibody to have a toxic effect on the target cells.

HL-60 cells were incubated for three days with increasing concentrations of either immunotoxin or gelonin in either the presence or absence of 5 nM retinoic acid. Afterwards, the cells were assayed for viability using the MTS assay. As seen in Figure 4, gelonin alone had no toxic effect in either the presence or absence of 5 nM. Thus, the toxic effect of gelonin depends on it being

conjugated to the anti-CD38 monoclonal antibody in order to deliver the toxin to the cell.

### EXAMPLE 5

Even nominal levels of all-*trans*-retinoic acid (RA) lead to increased toxicity of the immunotoxin.

HL-60 were incubated with either immunotoxin or unconjugated IB4 monoclonal antibody in increasing concentrations of monoclonal antibody. Figure 5 shows that even the lowest level of all-*trans*-retinoic acid (RA) (1 nM) lead to almost complete killing of the target cells by the immunotoxin. This effect was not observed with the unconjugated monoclonal antibody. This result indicates that it is the gelonin conjugated to the monoclonal antibody in the immunotoxin that leads to the increased cell death rather than some effect of the antibody itself.

## EXAMPLE 6

Retinoic acid can induce expression of the CD38 marker in a variety of cell lines.

5           The Daudi, THP-1, K562, and HL60-RAR $\alpha$  cell lines were treated with increasing concentrations of immunotoxin in either the presence or absence of 5 nM all-*trans*-retinoic acid (RA). After three days, the viability of the cells was examined using the MTS assay, which is shown in Figure 6. In the THP-1 and HL60-RAR $\alpha$  cell lines, 10 all-*trans*-retinoic acid induced cell death while the cell which were cultured in the absence of all-*trans*-retinoic acid were mostly unaffected by the immunotoxin. In the Daudi cells, which have a high basal expression of CD38, the immunotoxin resulted in almost complete cell death regardless of whether retinoic acid was present. 15 On the other hand, K562, which are resistant to RA-induced CD38 expression, were unaffected by the immunotoxin regardless of the presence of retinoic acid.

### EXAMPLE 7

Immunotoxin induced cell death in HL-60 cells resistant to Adriamycin.

HL-60 subcloned cells, resistant to adriamycin-induced killing were cultured with immunotoxin either alone or in the presence of 5 nM all-*trans*-retinoic acid. After three days, the MTS assay was used to test cell viability. Figure 7 shows the results obtained. Some cell death was observed in the presence of immunotoxin alone which was greatly augmented by the addition of 5 nM all-*trans*-retinoic acid.

### EXAMPLE 8

Cells which have high basal expression of CD38 are killed by immunotoxin regardless of the presence or absence of all-*trans*-retinoic acid (RA).

MZ, a non-Hodgkin lymphoma cell line which has a high basal expression of CD38, was treated with increasing amounts of immunotoxin in either the presence or absence of 5 nM all-*trans*-

retinoic acid. The addition of immunotoxin resulted in a high level of cell death regardless of the presence or absence of retinoic acid (Figure 8). This is strong evidence that retinoic acid is increasing the toxicity of immunotoxin by enhancing the level of CD38 on other cell lines which do not have a high basal level of CD38.

### **EXAMPLE 9**

Retinoic increases CD38 expression in a number of lymphoid tumor cells.

Table I lists the potential targets for anti-CD38 bound toxin treatment. A number of different lymphoid tumor cell lines were treated with 5 nM all-*trans*-retinoic acid (RA). Afterwards, the expression of CD38 in untreated versus treated cell was measured by flow cytometry. A significant rise in CD38 expression was observed in acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), lymphoma, and myeloma tumor cells. The increase in CD38 expression ranges from 2.5 to 20 fold. Thus, retinoic acid can be used in all of these tumor types to increase the vulnerability of the tumor cells to immunotoxin treatment.

### EXAMPLE 10

Immunotoxin does not affect cells resistant to all-*trans*-retinoic acid (RA)

HL-60 cells with a mutated RAR $\alpha$  gene that renders the cells resistant to the effects of retinoic acid were treated with immunotoxin in either the presence or absence of 5 nM retinoic acid. In these cells, the addition of retinoic acid had no effect on the toxicity of the immunotoxin. As shown in Figure 9, no appreciable cell death was observed in the cells treated with all-*trans*-retinoic acid (RA), with unconjugated IB4 and gelonin, or with gelonin alone. This is further proof that the immunotoxin kills cells which are affected by retinoic acid because of a retinoid induced increase in expression of CD38 target of the immunotoxin.

Any patents or publications mentioned in this specification are indicative of the levels of those skilled in the art to which the invention pertains. These patents and publications are herein incorporated by reference to the same extent as if each

individual publication was specifically and individually indicated to be incorporated by reference.

One skilled in the art will readily appreciate that the present invention is well adapted to carry out the objects and obtain the ends and advantages mentioned, as well as those inherent therein. The present examples along with the methods, procedures, treatments, molecules, and specific compounds described herein are presently representative of preferred embodiments, are exemplary, and are not intended as limitations on the scope of the invention. Changes therein and other uses will occur to those skilled in the art which are encompassed within the spirit of the invention as defined by the scope of the claims.

**WHAT IS CLAIMED IS:**

1. A method of treating an individual having a pathophysiological state, comprising the steps of:

5 a). administering to said individual a pharmacologically effective dose of a agent which up-regulates the expression of a cellular target; and,

10 b). administering to the same individual a pharmacologically effective dose of an immunotoxin directed against the up-regulated cellular target.

15 2. The method of claim 1, wherein the administered agent is selected from the group consisting of differentiating agents, cytokines, interleukin-2, tumor necrosis factor, interferon- $\alpha$ , interferon- $\gamma$  and peptide hormones.

20 3. The method of claim 1, wherein said agent is a retinoid and wherein said cell target is the CD38 antigen.

4. The method of claim 3, wherein said pathophysiological state is selected from the group consisting of acute myeloid leukemia, acute promyelocytic leukemia, lymphomas, and myelomas.

5. The method of claim 3, wherein said retinoid is selected from the group consisting of all-*trans*-retinoic acid (RA); 9-*cis* retinoic acid (9-*cis* RA); (*E*)-4-[2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl]benzoic acid (TTNPB); (*E*)-4-[2-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)-1-propenyl]benzoic acid (3-met TTNPB).

6. The method of claim 5, wherein said retinoid is administered in a dose of from about 0.1 mg/kg to about 2 mg/kg.

7. The method of claim 3, wherein said immunotoxin specifically targets cells expressing the CD38 antigen.

8. The method of claim 7, wherein said immunotoxin comprises a monoclonal antibody directed against the CD38 antigen conjugated to a toxin molecule.

9. The method of claim 8, wherein said toxin is gelonin.


10. The method of claim 8, wherein the monoclonal antibody is selected from the group consisting of IB4 or IB6.

11. The method of claim 1, wherein said immunotoxin is administered in a dose of from about 0.05 mg/kg to about 2 mg/kg.

## **ABSTRACT OF THE DISCLOSURE**

The present invention is directed to the use of agents that induce high levels of cell surface molecules to provide targets for immunotoxins directed against the same cell surface molecules. A specific example is given in which all-*trans*-retinoic acid (RA) is used to induce high levels of CD38 cell surface antigen expression in several myeloid and lymphoid leukemia cells. CD38 was then used as target for delivering plant toxin (gelonin) to leukemia cells. Treatment of leukemia cells with RA induced high levels of CD38 in those cells that otherwise had low CD38 expression. The RA-induced leukemia cells then became exquisitely sensitive to an immunotoxin constructed from an anti-CD38 monoclonal antibody conjugated to the plant toxin gelonin.

## MoAb-based therapy of Cancer: CD38 expression in normal human tissues



Legend: Master blot from Clontech was hybridized with radiolabeled human CD38-specific nucleic acid probe. Only the thymus tissue (from adult and fetal) showed mRNA transcript for CD38. Prostate was also positive but to a lesser extent.

Figure 1

## MoAb-based therapy of Cancer: Reversal effect of unconjugated anti-CD38 moAb on IT-induced cytotoxicity in HL-60 cells

**Legend:** HL-60 cells were incubated With IT alone (C) or IT+RA (5nM) In presence or absence of increasing Concentrations unconjugated anti-CD38 moAb. Cell viability was Tested fter 3 days incubation by using MTS assay




Figure 2

# Effect of RA-prereatment on IT-Induced Killing of HL-60 cells

**Legend:** HL-60 were incubated with or without RA (5 nM) overnight, washed twice and then recultured in the presence or absence of IT alone or in the presence of 100-fold excess of nonconjugated anti-CD38 mAb. After 3 days incubation cell viability was terminated using MTS assay




Figure 3

## MoAb-based therapy of Cancer: IB4-gelonin-induced killing of HL-60 cells in presence of RA

**Legend:** HL-60 cells were incubated  
For 3 days in presence of IT or gelonin  
Alone or in presence of 5 nM RA.  
Cell viability was checked by MTS assay.




Figure 4

# MoAb-based therapy of Cancer: Effect of increasing RA conc.

**Legend:** HL-60 were cultured in presence Of IT or unconjugated anti-CD38 moAb Alone the presence of increasing amounts of RA For 3 days. At the end of incubation, cell viability Was determined by MTS assay






Figure 5

## Daudi



## K562





Figure 6

# MoAb-based therapy of Cancer:

## IT-induced killing of Doxo-resistant HL-60 cells

**Legend:** HL-60 subcloned cells, resistant to Adriamycin-induced killing were cultured With IT alone in the presence of 5 nM RA. After 3 days incubation, cells viability was tested using MTS assay.




Figure 7

# MoAb-based therapy of Cancer:

## IT-mediated killing of MZ (NHL) cells

**Legend:** A non-Hodgkin lymphoma cell line that has a high basal expression of CD38 antigen was incubated with IT in presence or absence of RA. The cell cell viability was checked after 3 days culture using MTS assay.




Figure 8

**Legend:** An HL-60 subclone with mutated RARalpha genethat renders these cells resistant to RA-induced CD38 expression, was cultured with IT alone or in presence of 5 mM RA. After 3 days the cell viability was determined using MTS assay.




Figure 9

Potential targets for anti-CD38 bound toxin treatment

Cell target	Basal CD38	CD38 after RA treatment
AML	$50 \pm 10$	$180 \pm 20$
APL	$6 \pm 4$	$120 \pm 30$
Lymphomas	$80 \pm 20$	$210 \pm 10$
Myelomas	$60 \pm 20$	$180 \pm 25$
SLE	B cells producing self reactive ab Self reactive T lymphocyte	
Myesthenia gravis		
Rheumatoid arthritis		
Organ Transplantation		

Table 1

DOCKET NO: D6205

**COMBINED DECLARATION AND POWER OF ATTORNEY**

I, **Michael Rosenblum**, hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and co-inventor, together with Kapil Mehta, of the subject matter which is claimed and for which a patent is sought on the invention entitled, **Potentiation of Anti-CD38-Immunotoxin Cytotoxicity**; the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, 37 CFR §1.56(a).

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Dr. Benjamin Adler, Registration No. 35,423 and Sarah J. Brashears, Registration No. 38,087. Address all telephone calls to Dr. Benjamin Adler at telephone number 713/777-2321. Address correspondence to Dr. Benjamin Adler, MCGREGOR & ADLER, L.L.P., 8011 Candle Lane, Houston, TX 77071.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: Michael Rosenblum

Inventor's Signature: *Michael Rosenblum* Date: 1/7/99

Residence Address: 3127 Stoney Mist Dr., Sugar Land, TX 77479

Citizen of: United States of America

Post Office Address: Sugar Land, TX 77479

09225895 010799

DOCKET NO: D6205

**COMBINED DECLARATION AND POWER OF ATTORNEY**

I, Kapil Mehta, hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; I believe I am the original, first and co-inventor, together with Michael Rosenblum, of the subject matter which is claimed and for which a patent is sought on the invention entitled, **Potentiation of Anti-CD38-Immunotoxin Cytotoxicity**; the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose all information I know to be material to patentability in accordance with Title 37, Code of Federal Regulations, 37 CFR §1.56(a).

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: Dr. Benjamin Adler, Registration No. 35,423 and Sarah J. Brashears, Registration No. 38,087. Address all telephone calls to Dr. Benjamin Adler at telephone number 713/777-2321. Address correspondence to Dr. Benjamin Adler, MCGREGOR & ADLER, L.L.P., 8011 Candle Lane, Houston, TX 77071.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patents issued thereon.

Full Name of Inventor: Kapil Mehta

Inventor's Signature: Kapil Mehta Date: Jan 7, 1999

Residence Address: 5863 BRAESHEATHER DR, Houston, Tx 77096

Citizen of: INDIA

Post Office Address: \_\_\_\_\_

0026895-0109

Applicant or Patentee: Mehta et al Attorney's  
Serial or Patent No.: \_\_\_\_\_ Docket No.: 6205  
Filed or Issued: January 7, 1999  
For: Potentiation of Anti-CD38-Immunotoxin Cytotoxicity

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS (37 CFR 1.9(f) and 1.27(c)) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official of the nonprofit organization empowered to act on behalf of the concern identified below:

NAME OF ORGANIZATION: Research Development Foundation  
ADDRESS OF CONCERN: 402 North Division Street  
Carson City, Nevada 89703

TYPE OF ORGANIZATION:

☒ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 USC 501(a) AND 501(c)(3))

I hereby declare that the above identified nonprofit organization qualifies as a nonprofit organization as defined in 37 CFR 1.9(e), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization identified above with regard to the invention, entitled as above by inventor(s) as above described in

☒ the specification filed herewith  
☐ application serial no. \_\_\_\_\_, filed \_\_\_\_\_  
☐ patent no. \_\_\_\_\_, issued \_\_\_\_\_

If the rights held by the above identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

\*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

NAME \_\_\_\_\_  
ADDRESS \_\_\_\_\_

☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING: JAMES F. WEILER  
TITLE OF PERSON OTHER THAN OWNER: VICE PRESIDENT  
ADDRESS OF PERSON SIGNING ONE RIVERWAY, SUITE 1560, HOUSTON, TEXAS 77056  
SIGNATURE: James F. Weiler  
DATE: 1-7-99